Somatically mutated ABL1 is an actionable and essential NSCLC survival gene

EMBO Molecular Medicine

Volumn 8, Issue 2, 2016, Pages 105-116

  Testoni, Ewelina ^a   Stephenson, Natalie L ^a   Torres Ayuso, Pedro ^a   Marusiak, Anna A ^a   Trotter, Eleanor W ^a   Hudson, Andrew ^a   Hodgkinson, Cassandra L ^a   Morrow, Christopher J ^a   Dive, Caroline ^a   Brognard, John ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

ABL1 mutations; Dasatinib; Imatinib; Non small cell lung cancer

Indexed keywords

BCR ABL PROTEIN; DASATINIB; HYBRID PROTEIN; IMATINIB; ABELSON KINASE; ANTINEOPLASTIC AGENT; MUTANT PROTEIN;

ARTICLE; CANCER SURVIVAL; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; GENE MUTATION; HUMAN; IN VIVO STUDY; LUNG CANCER CELL LINE; MUTATIONAL ANALYSIS; NON SMALL CELL LUNG CANCER; OXIDATIVE STRESS; PRIORITY JOURNAL; RECIPROCAL CHROMOSOME TRANSLOCATION; SOMATIC MUTATION; TUMOR GROWTH; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE MODEL; DRUG EFFECTS; GENETICS; MOUSE; TREATMENT OUTCOME; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; HETEROGRAFTS; HUMANS; IMATINIB MESYLATE; MICE; MUTANT PROTEINS; PROTO-ONCOGENE PROTEINS C-ABL; TREATMENT OUTCOME;

EID: 84957938432     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.15252/emmm.201505456     Document Type: Article

References (28)

1. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehar J, Kryukov GV, Sonkin D et al (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483: 603-607
2. Bixby D, Talpaz M (2009) Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematology Am Soc Hematol Educ Program 2009: 461-476
3. Brognard J, Zhang YW, Puto LA, Hunter T (2011) Cancer-associated loss-of-function mutations implicate DAPK3 as a tumor-suppressing kinase. Cancer Res 71: 3152-3161
4. Cheung HW, Du J, Boehm JS, He F, Weir BA, Wang X, Butaney M, Sequist LV, Luo B, Engelman JA et al (2011) Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov 1: 608-625
5. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB et al (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455: 1069-1075
6. Druker BJ (2008) Translation of the Philadelphia chromosome into therapy for CML. Blood 112: 4808-4817
7. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2: 561-566
8. Fawdar S, Trotter EW, Li Y, Stephenson NL, Hanke F, Marusiak AA, Edwards ZC, Ientile S, Waszkowycz B, Miller CJ et al (2013) Targeted genetic dependency screen facilitates identification of actionable mutations in FGFR4, MAP3K9, and PAK5 in lung cancer. Proc Natl Acad Sci USA 110: 12426-12431
9. Furstoss O, Dorey K, Simon V, Barila D, Superti-Furga G, Roche S (2002) c-Abl is an effector of Src for growth factor-induced c-myc expression and DNA synthesis. EMBO J 21: 514-524
10. Ganguly SS, Fiore LS, Sims JT, Friend JW, Srinivasan D, Thacker MA, Cibull ML, Wang C, Novak M, Kaetzel DM et al (2012) c-Abl and Arg are activated in human primary melanomas, promote melanoma cell invasion via distinct pathways, and drive metastatic progression. Oncogene 31: 1804-1816
11. Greuber EK, Smith-Pearson P, Wang J, Pendergast AM (2013) Role of ABL family kinases in cancer: from leukaemia to solid tumors. Nat Rev Cancer 13: 559-571
12. Heist RS, Engelman JA (2012) SnapShot: non-small cell lung cancer. Cancer Cell 21: 448.e2
13. Hunter T (2007) Treatment for chronic myelogenous leukemia: the long road to imatinib. J Clin Investig 117: 2036-2043
14. Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J et al (2012) Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst 104: 228-239
15. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2011) Animal research: reporting in vivo experiments-the ARRIVE guidelines. J Cereb Blood Flow Metab 31: 991-993
16. Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao A, Stewart DJ, Hicks ME, Erasmus J, Gupta S et al (2011) The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 1: 44-53
17. Kornev AP, Taylor SS, Ten Eyck LF (2008) A helix scaffold for the assembly of active protein kinases. Proc Natl Acad Sci USA 105: 14377-14382
18. Kundu P, Genander M, Straat K, Classon J, Ridgway RA, Tan EH, Bjork J, Martling A, van Es J, Sansom OJ et al (2015) An EphB-Abl signaling pathway is associated with intestinal tumor initiation and growth. Sci Transl Med 7: 281ra244
19. Lin J, Sun T, Ji L, Deng W, Roth J, Minna J, Arlinghaus R (2007) Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1. Oncogene 26: 6989-6996
20. Politi K, Herbst RS (2015) Lung cancer in the era of precision medicine. Clin Cancer Res 21: 2213-2220
21. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J (2000) Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289: 1938-1942
22. Seo JH, Wood LJ, Agarwal A, O'Hare T, Elsea CR, Griswold IJ, Deininger MW, Imamoto A, Druker BJ (2010) A specific need for CRKL in p210BCR-ABL-induced transformation of mouse hematopoietic progenitors. Cancer Res 70: 7325-7335
23. Shah NP, Kasap C, Weier C, Balbas M, Nicoll JM, Bleickardt E, Nicaise C, Sawyers CL (2008) Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 14: 485-493
24. Taagepera S, McDonald D, Loeb JE, Whitaker LL, McElroy AK, Wang JY, Hope TJ (1998) Nuclear-cytoplasmic shuttling of C-ABL tyrosine kinase. Proc Natl Acad Sci USA 95: 7457-7462
25. Tokarski JS, Newitt JA, Chang CY, Cheng JD, Wittekind M, Kiefer SE, Kish K, Lee FY, Borzillerri R, Lombardo LJ et al (2006) The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 66: 5790-5797
26. Vigneri P, Wang JY (2001) Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med 7: 228-234
27. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA, Glennie MJ et al (2010) Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102: 1555-1577
28. Zhao H, Chen MS, Lo YH, Waltz SE, Wang J, Ho PC, Vasiliauskas J, Plattner R, Wang YL, Wang SC (2014) The Ron receptor tyrosine kinase activates c-Abl to promote cell proliferation through tyrosine phosphorylation of PCNA in breast cancer. Oncogene 33: 1429-1437